The IDO inhibitor D‐1‐methyltryptophan enhances the antitumor efficacy of oxaliplatin [88], while the combination of a stimulator of interferon (IFN) genes with an IDO inhibitor significantly suppresses CRC progression [89]. The gene discussed is IDO1; the disease is colorectal carcinoma.